The Future of Migraine Prevention

Abstract

Barring unforeseen circumstances, we anticipate the arrival of the first mechanism‐specific class of molecules for migraine prevention in 2018. Despite many ground‐breaking advances in the field over the last several years, these agents, broadly identified as calcitonin gene‐related peptide‐based pharmaceuticals, have captured the imagination and attention of the lay press and much of the headache community. This paper will address the factors, both class‐specific and systems‐based, that are likely to affect the launch, access, compliance, and adherence related to this new class, as well as attempt to place these novel medications in context of the current state and anticipated changes in headache medicine.